Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects

Area of Science:

• Pulmonary Drug Delivery
• Oncology
• Pharmaceutical Sciences

Background:

• Inhaled chemotherapy has shown potential since 1968 but has not reached the market due to technological and clinical hurdles.
• Optimizing drug efficacy and tolerance is key to advancing inhaled chemotherapy development.
• Evolving lung cancer treatment standards create opportunities for combining inhaled chemotherapy with existing therapies.

Purpose of the Study:

• To review clinical and technological challenges in inhaled chemotherapy.
• To explore novel pharmaceutical developments and formulation strategies.
• To discuss new clinical strategies considering immunotherapy's impact.

Main Methods:

• Focus on dry powder inhalers for drug delivery.
• Investigate formulation strategies including controlled release, sustained lung retention, and nanomedicine.
• Analyze clinical strategies in the context of modern lung cancer care.

Main Results:

• Identified key factors for optimizing inhaled chemotherapy: drug selection, device, formulation, and clinical integration.
• Highlighted the importance of addressing technological and clinical challenges for market entry.
• Emphasized the potential of new approaches to improve local tolerance and efficacy.

Conclusions:

• Overcoming existing challenges is crucial for the future of inhaled chemotherapy.
• Advanced drug delivery systems and tailored formulations are essential.
• Strategic integration into patient care, especially with immunotherapy, offers new therapeutic avenues.